LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

The market value of the company surpassed the size of Denmark’s entire economy last year and, for a period, Novo Nordisk was ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Global pharmaceutical giants make billions of dollars in Australia but pay a fraction of that in tax. They say the price they ...

The FTSE 100 tracked about a third of a per cent lower this morning amid with another stack of earnings to digest and a key three days in the US likely to set the tone. The S&P 500 slid 0.3 per cent ...

Today, we are on the lookout for more than 170 reports per Nasdaq. Many of them happened this morning. Here were the top 10 reports (by market cap) happening in the A.M. Here are some of the ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...